Cocrystal Pharma Q2 FY26 net loss widens to $3.16 million; R&D expense climbs to $2.14 million

Cocrystal Pharma posted a net loss of $3.16 million for the quarter ended June 30, 2026, widening from $2.06 million a year earlier.

Research and development expense climbed to $2.14 million from $1.12 million, due to CDI-988 entering a norovirus Phase 1a clinical trial in 2026.

General and administrative costs rose to $1.15 million from $986,000, on higher professional fees and insurance expense.

Grant income was $105,000 versus no grant income a year earlier; interest income slipped to $10,000 from $28,000.

Unrestricted cash totaled $2.17 million at June 30, 2026; a July 31 stock sale raised $5 million in gross proceeds.